Obsidian Therapeutics to Present Updated Amsoki-cel Data at SITC 2026

Obsidian Therapeutics will present updated Phase 1/2 data for its Amsoki-cel (OBX-115) therapy in advanced melanoma patients at the SITC 2026 Annual Meeting.